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The only gangliosides in Burkitts’ lymphoma EB-3 cells is GM3. Treatment of Burkitts’ l~phoma EB-3 cells with ganglosides GM1 or GM3 
results in their binding to and partial incorporation into the cell membrane. About 25% of cell-associated ganglioside GMI can interact with the 
ricin. However, such an increase in the number of binding sites does not enhance but rather decreases the cytotoxic effect of ricin. A similar protec- 
tive effect was observed when the cells were pretreated with ganghoside GM3. In contrast, the increase in ricin binding sites caused by pretreatment 
of the cells with neuraminidase was accompanied by increase in ricin cytotoxicity. These differences may be related to observed ifferences in the 
rate of ricin-endocytosis by native and ganglioside-treated cells. 
Ricin; Receptor; Ganglioside 
1. INTRODUCTION 
The plant toxin ricin is a 62 kDa glycoprotein con- 
sisting of two disulfide-bonded subunits [2]. The A 
chain (30 kDa) catalytically inactivates eukaryotic 
ribosomes [3]. The B chain (32 kDa) is a lectin that 
binds to galactose or N-acetylgalactosamine r sidues on 
the cell surface 141. It is not clear, however, whether all 
such glycoconjugate molecules can serve as true recep- 
tors of the toxin (in the sense that they promote transfer 
of the toxin into the cytosol) or if only a subpop~ation 
of the ricin binding sites is able to induce entry of the 
toxin. We have recently shown that Burkitts’ lym- 
phoma EB-3 cells contain two types of ricin binding 
sites [5]. To elucidate the nature of ricin receptors in 
Burkitts’ lymphoma cells, we determined in the present 
study the binding of ricin to and its cytotoxic action on 
native cells, neuraminidase-treated cells and cells load- 
ed with either ganglioside GM1 which contains a ter- 
minal galactose and can effectively bind ricin in model 
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Abbreviations: BSA, bovine serum albumin; DMPC, l,Zdimiristoyl- 
phosphatidylcholine; ASM, anthrylvinyl-labeled sphingomyelin 
(N-12-(9-anthryl)-trans-dodecenoylsphingosine-l-phosphocholine). 
Abbreviations of gangliosides follow the nomenclature of [l]: GMI, 
Gal~-3)GalNAc~1-4)NeuAc(cu2-3)Gal~1-4)Gal~l-l)Cer; GM3, 
NeuAc(aZ-3GaI@ -4)Glc(&l-1 )Cer 
systems [6,16] or with GM3 having a terminal sialic 
acid residue. 
2. MATERIALS AND METHODS 
Burkitts’ lymphoma EB-3 cells were cultured in DMEM (Flow 
Labs) supplemented with 10% FCS (Flow Labs), 2 mM glutamine 
and canamycin (100 pg/ml) at 37°C in a humidified atmosphere with 
5% CO2 in air. 
Ricin and its constituent polypeptide chains were isolated by the 
method described in [7,8]. Labeling of ricin B-chain with iodine-125 
was performed according to ]9] in the presence of 50 mM lactose. 
Rabbits were immunized with ricin B-chain and antibodies were 
isolated using B-chain-Sepharose. 
Binding of [“‘I]B-chain and anti-B-chain antibodies was prepared 
as described in [lo]. 
GMl, GM3 and labeled [‘H]GM 1, [‘H]GM3 with a specific activi- 
ty of 400 and 800 mCi/mM, respectively, were kindly provided by Dr 
N.V. Prokasova. The concentration of gangliosides in the incubation 
mixture containing 10’ cells/ml was 200 CM. Uptake of ganghosides 
was determined after repeated washing of the cells. 
The fluorescent probe ASM was kindly provided by Dr 3.G. 
Molotkovsky. Fluorescent labeling and fluorescence anisotropy 
m~surement were prepared as described by Manevich et al. [I 11. 
Treatment of cells with neuram~niduse. Washed lymphoma ceils 
(10’ cells/ml) were treated with neuraminidase from Vibrio cholera 
(Sigma) (50 U/ml) in Hanks’ solution containing 1 mg/mI BSA 
(Calbiochem), for 1 h at 37°C [If]. 
The cytotoxic effect of ricin was determined by measuring the in- 
hibition of [‘%Jleucine incorporation into EB-3 cells caused by the 
toxin [12]. 
Small unilamellar liposomes were prepared by evaporation in 
vacua of DMPC intermixed with ganglioside GM1 (9: 1 M/M) solu- 
tion in chloroform. The mixture was then suspended in PBS contain- 
ing 1 mM EDTA, and sonicated for 5 min in a nitrogen atmosphere 
(50 W, 22-28 kHz; Labline Incf at 0°C. After sonication the suspen- 
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sion was kept at 28’C for 2 h. The main phase transition was 
registered by liposome turbidity measurement 1141 at 350 nm using a 
Beckman DU-8 (USA) spectrophotometer. 
3. RESULTS AND DISCUSSION 
3.1. Loading of Burkifts’ lynphoma cells with 
gangliosides 
Preliminary experiments demonstrated that upon in- 
cubation of the cells with increasing amounts of 
gangliosides in the S-ZOO PM range, maximal binding 
was achieved after 20-30 min and the amount of cell- 
associated ganglioside increased linearly with the 
amount of ganglioside added [9]. 
After incubation of Burkitts’ lymphoma cells the 
trypsin-resistant cell-associated ganglioside GM1 cor- 
responded to about 40% of the total cell-associated 
ganglioside [9]. Earlier it was shown that incubation of 
gangliosides with mouse fibroblasts was not accom- 
panied by ganglioside endocytosis and that all cell- 
associated gangliosides remained on the cell surface 
[15]. If this holds true also for EB-3 cells, their incuba- 
tion with GM1 should result in the appearance of about 
10’ additional ricin binding sites’ on the surface of each 
cell. 
3.2. Binding of ricin B-chain to native and modeled 
EB-3 cells 
The binding of ‘251-ricin B-chain to Burkitts’ lym- 
phoma cells was determined by radioligand 
measurements. The number of high-affinity (& 
10” M-‘) and low affinity (& lo8 M-l) binding sites 
comprised lo4 per cell and lo6 per cell, respectively 
(Fig. IA). 
Neuraminidase treatment of EB-3 cells led to ap- 
pearance of additional terminal galactose residues and 
resulted in a 12-l&fold increase of B-chain binding 
(Table I and Fig. 1B). Comparison of these data with 
the number of lipid-bound terminal galactoses appear- 
ing on the cell surface after neuraminidase treatment 
[9] demonstrated that the larger part (80%) of the B- 
chain-binding sites’ increase must be due to protein- 
bound galactoses, which before neuraminidase treat- 
ment were masked. 
Loading of the cells with exogenous GM1 led to a 
2-3-fold increase of ricin B-chain binding, whereas 
loading of the cells with GM3 had no effect on the bin- 
ding of B-chain (Table I). 
3.3. Effect of cell treatment on rich endocytosis rate 
and cytotoxic action 
The 12-l&fold increase in ‘251-ricin B-chain binding 
following neuraminidase treatment of Burkitts’ lym- 
phoma cells (Table I) was accompanied by a marked in- 
crease in ricin cytotoxicity (Fig. 2). Contrary to this, 
the ricin-sensitivity of the ganglioside-loaded cells was 
about 2 times lower than that of control cells. A similar 
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Fig. 1. Binding of the ricin B-chain to native (A) and neuraminidase- 
treated (B) Burkitts’ lymphoma cells. Data are presented in Scatchard 
coordinates, where r is the number of ricin B-chain molecules bound 
to one cell, and c the concentration of non-bound ricin B-chain in 
mol/l. Values are averages of quadruplicate incubations from a single 
experiment. 
cells with ganglioside GM3. Loading of the cells with 
ganglioside GM1 resulted in a decrease of the en- 
docytosis rate: after 20 min incubation of &in-treated 
GMl-loaded cells the binding of anti-ricin B-chain- 
antibodies was two times higher than in ricin-treated 
control cells, but after 60 min incubation about 90% of 
the cell-associated ricin became inaccessible to anti- 
ricin B-chain-antibodies both in GMl-loaded cells and 
in control cells (Table II). A similar decrease in the rate 
of ricin endocytosis after treatment of cells with con- 
Table 1 
Binding of ‘2SI-ricin B-chain to Burkitts’ lymphoma cells pretreated 
with neuraminidase or gangliosides 
Concentration of Cell-bound %ricin B-chain 
“‘1-ricin B-chain (10’ cpm - min- ‘) 
(IO3 cpm.ml-‘.min-‘) 
Buffer Cells treated with 
Neuramin- GM1 GM3 
idase 
16 2.0 25 5.0 2.2 
70 5.7 93 13.5 5.2 
250 8.6 _ 26.8 8.8 
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Fig. 2. Cytotoxic action of ricin on native EB-3 cells (0), cells 
pretreated with neuraminidase (+), cells loaded with ganglioside 
GM1 (A) and ganglioside GM3 (x). 
canavalin A, was ascribed to an increase in the rigidity 
of the plasma membrane effected by the lectin [17]. 
3.4. Effect of ricin binding on cell membranes and 
liposomes 
Earlier the binding of ricin to Burkitts’ lymphoma 
cells was studied using a fluorescence method based on 
measurement of the ligand-induced changes in the 
fluorescence anisotropy of the concentration- 
dependent, saturable fashion [5]. In the present study 
loading of ASM-labeled EB-3 cells with ganglioside 
GM1 resulted in some decrease of the ASM- 
fluorescence anisotropy (approximately 8%) (and 
hence probably in a somewhat more fluid plasma mem- 
brane) but upon addition of ricin B-chain (lo6 
molecules per cell) no additional change in the 
fluorescence polarization (as compared to ASM-labeled 
control cells) was observed. 
As can be seen from Fig. 3, ricin and B-chain in- 
creased the abruptness of the phase transition of 
DMPC-liposomes containing 2 M% GM1 indicating an 
increase in cooperativity of the phase transition. With 
increasing GM1 concentration the phase transition of 
Table II 
Binding of ‘251-labeled anti-ricin B-chain-antibodies to ricin-treated 
lymphoma cells 
Time of incubation at 37°C 
before addition of antibodies 




Vo of bound antibodiesa 




a % of bound antibodies = (binding of “‘I-antibodies after 
incubation at 37YYbinding of ‘*sI-antibodies at 0°C) x 100% 
24 
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Fig. 3. Influence of ricin (+) and ricin B-chain (x) on the phase 
transition of DMPC-liposomes containing 2 M% of GM1 at pH 7.5, 
registered by turbidity measurement; (0) liposomes without any 
protein. 
DMPC in the presence of ricin B-chain was broadened 
(Fig. 4) testifying to a loss in cooperativity. This 
phenomenon may be explained in terms of ganglioside 
clustering induced by the ricin B-chain. 
As noted above, loading of EB-3 cells with GM1 by 
contrast, increases the apparent fluidity of the plasma 
membrane. However, it is not excluded that in the 
presence of ricin gangliosides cluster around glycopro- 
tein receptors of ricin, forming rigid microdomains im- 
peding endocytosis. 
In conclusion, the combined data of the present 
study show that GM1 and, probably related 
glycolipids, which have terminal galactoses, are not the 
true receptors of ricin. Probably the true ricin receptors 
belong to the relatively small population of molecules 
binding the toxin with higher affinity. 
1.10 
r 
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Fig. 4. Influence of GM1 on the phase transition of DMPC- 
liposomes preincubated with ricin B-chain at pH 7.5: (x) 2 M% 
GMl; (0) 4 M% GMl; (A) 8 M% GMl. 
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